Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase

Hepatitis C virus (HCV) has infected almost 200 million people worldwide, typically causing chronic liver damage and severe complications such as liver failure. Currently, there are few approved treatments for viral infection. Thus, the HCV RNA‐dependent RNA polymerase (gene product NS5B) has emerged as an important target for small molecule therapeutics. Potential therapeutic agents include allosteric inhibitors that bind distal to the enzyme active site. While their mechanism of action is not conclusively known, it has been suggested that certain inhibitors prevent a conformational change in NS5B that is crucial for RNA replication. To gain insight into the molecular origin of long‐range allosteric inhibition of NS5B, we employed molecular dynamics simulations of the enzyme with and without an inhibitor bound to the thumb domain. These studies indicate that the presence of an inhibitor in the thumb domain alters both the structure and internal motions of NS5B. Principal components analysis identified motions that are severely attenuated by inhibitor binding. These motions may have functional relevance by facilitating interactions between NS5B and RNA template or nascent RNA duplex, with presence of the ligand leading to enzyme conformations with narrower and thus less accessible RNA binding channels. This study provides the first evidence for a mechanistic basis of allosteric inhibition in NS5B. Moreover, we present evidence that allosteric inhibition of NS5B results from intrinsic features of the enzyme free energy landscape, suggesting a common mechanism for the action of diverse allosteric ligands. Proteins 2013. © 2012 Wiley Periodicals, Inc.

[1]  T. Weikl,et al.  Selected‐fit versus induced‐fit protein binding: Kinetic differences and mutational analysis , 2008, Proteins.

[2]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[3]  D. Graham,et al.  Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors. , 2009, Journal of molecular biology.

[4]  Meitian Wang,et al.  Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition. , 2006, Journal of molecular biology.

[5]  R. Nussinov,et al.  The role of dynamic conformational ensembles in biomolecular recognition. , 2009, Nature chemical biology.

[6]  Meitian Wang,et al.  Crystal Structures of the RNA-dependent RNA Polymerase Genotype 2a of Hepatitis C Virus Reveal Two Conformations and Suggest Mechanisms of Inhibition by Non-nucleoside Inhibitors* , 2005, Journal of Biological Chemistry.

[7]  Ioan Andricioaei,et al.  On the calculation of entropy from covariance matrices of the atomic fluctuations , 2001 .

[8]  J. Duan,et al.  N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies. , 2010, Bioorganic & medicinal chemistry letters.

[9]  S. Harper,et al.  Mechanismof Action and Antiviral Activity of Benzimidazole-Based AllostericInhibitors of the Hepatitis C Virus RNA-Dependent RNAPolymerase , 2003, Journal of Virology.

[10]  J. Lescar,et al.  RNA-dependent RNA polymerases from flaviviruses and Picornaviridae. , 2009, Current opinion in structural biology.

[11]  R. Bartenschlager,et al.  The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. , 2006, Journal of hepatology.

[12]  Oliver F. Lange,et al.  Can principal components yield a dimension reduced description of protein dynamics on long time scales? , 2006, The journal of physical chemistry. B.

[13]  J. Jiricny,et al.  RNA-dependent RNA polymerase of hepatitis C virus. , 1996, Methods in enzymology.

[14]  Satoru Ikeda,et al.  Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors. , 2006, Journal of medicinal chemistry.

[15]  Hui Li,et al.  Identification and structure-based optimization of novel dihydropyrones as potent HCV RNA polymerase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[16]  S. Vasavanonda,et al.  Mechanistic study of HCV polymerase inhibitors at individual steps of the polymerization reaction. , 2006, Biochemistry.

[17]  Gordana Ivosev,et al.  Dimensionality reduction and visualization in principal component analysis. , 2008, Analytical chemistry.

[18]  P. Simister,et al.  A Comprehensive Structure-Function Comparison of Hepatitis C Virus Strain JFH1 and J6 Polymerases Reveals a Key Residue Stimulating Replication in Cell Culture across Genotypes , 2011, Journal of Virology.

[19]  Shichen Wang,et al.  Molecular Dynamics Analysis Reveals Structural Insights into Mechanism of Nicotine N-Demethylation Catalyzed by Tobacco Cytochrome P450 Mono-Oxygenase , 2011, PloS one.

[20]  K. Buck Comparison of The Replication of Positive-Stranded Rna Viruses of Plants and Animals , 1996, Advances in Virus Research.

[21]  N. Habuka,et al.  Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. , 1999, Structure.

[22]  Coray M. Colina,et al.  Molecular Dynamics Simulations of Viral RNA Polymerases Link Conserved and Correlated Motions of Functional Elements to Fidelity , 2011, Journal of Molecular Biology.

[23]  J. E. Robinson,et al.  Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[24]  A. Ramanathan,et al.  Computational identification of slow conformational fluctuations in proteins. , 2009, The journal of physical chemistry. B.

[25]  M. Komatsu,et al.  The essential role of C-terminal residues in regulating the activity of hepatitis C virus RNA-dependent RNA polymerase. , 2002, Biochimica et biophysica acta.

[26]  Kyoung Tai No,et al.  Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. , 2009, Bioorganic & medicinal chemistry.

[27]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[28]  Matthias Rarey,et al.  Recore: A Fast and Versatile Method for Scaffold Hopping Based on Small Molecule Crystal Structure Conformations , 2007, J. Chem. Inf. Model..

[29]  David L. Beveridge,et al.  Dynamical allosterism in the mechanism of action of DNA mismatch repair protein MutS. , 2011, Biophysical journal.

[30]  Robert A. Love,et al.  Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme , 2003, Journal of Virology.

[31]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[32]  Isabelle Bougie,et al.  Characterization of the Metal Ion Binding Properties of the Hepatitis C Virus RNA Polymerase* , 2003, The Journal of Biological Chemistry.

[33]  P. Simister,et al.  An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors. , 2011, Journal of molecular biology.

[34]  D. Lamarre,et al.  Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate. , 2004, Nucleic acids research.

[35]  Hui Li,et al.  Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. , 2009, Journal of medicinal chemistry.

[36]  Alexander D. MacKerell,et al.  Atomistic Models and Force Fields , 2001 .

[37]  P. Beaulieu Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection , 2009, Expert opinion on therapeutic patents.

[38]  Francisco Parra,et al.  Structure and function of RNA replication. , 2006, Annual review of microbiology.

[39]  S. LaPlante,et al.  Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategy. , 2004, Angewandte Chemie.

[40]  N. Walker,et al.  Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerases. , 2006, Journal of molecular biology.

[41]  Ching-Hsing Yu,et al.  Systematic study of anharmonic features in a principal component analysis of gramicidin A. , 2010, Biophysical journal.

[42]  Z. A. Wood,et al.  Role of packing defects in the evolution of allostery and induced fit in human UDP-glucose dehydrogenase. , 2011, Biochemistry.

[43]  Vladimir D. Axelrod,et al.  Modulation of Hepatitis C Virus RNA-dependent RNA Polymerase Activity by Structure-based Site-directed Mutagenesis* , 2002, Journal of Biological Chemistry.

[44]  Interdomain communication in HCV polymerase abolished by small-molecule inhibitors , 2005 .

[45]  Meitian Wang,et al.  Non-nucleoside Analogue Inhibitors Bind to an Allosteric Site on HCV NS5B Polymerase , 2003, The Journal of Biological Chemistry.

[46]  Isabelle Bougie,et al.  Effect of Metal Ion Binding on the Structural Stability of the Hepatitis C Virus RNA Polymerase* , 2004, Journal of Biological Chemistry.

[47]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[48]  R. Chopra,et al.  Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796 , 2008, Antimicrobial Agents and Chemotherapy.

[49]  J. E. Robinson,et al.  Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure-activity relationships of benzothiazine-substituted quinolinediones. , 2009, Bioorganic & medicinal chemistry letters.

[50]  M. Cummings,et al.  1a/1b Subtype Profiling of Nonnucleoside Polymerase Inhibitors of Hepatitis C Virus , 2010, Journal of Virology.

[51]  Charles M. Rice,et al.  Unravelling hepatitis C virus replication from genome to function , 2005, Nature.

[52]  E. H. Rydberg,et al.  Identification and biological evaluation of a series of 1H-benzo[de]isoquinoline-1,3(2H)-diones as hepatitis C virus NS5B polymerase inhibitors. , 2009, Journal of medicinal chemistry.

[53]  R. Francesco,et al.  Identification and properties of the RNA‐dependent RNA polymerase of hepatitis C virus. , 1996, The EMBO journal.

[54]  Nuria Verdaguer,et al.  A comparison of viral RNA-dependent RNA polymerases. , 2006, Current opinion in structural biology.

[55]  Youhoon Chong,et al.  Identification of Novel HCV RNA‐dependent RNA polymerase Inhibitors Using Pharmacophore‐Guided Virtual Screening , 2008, Chemical biology & drug design.

[56]  Isabelle Bougie,et al.  Metal ion-binding studies highlight important differences between flaviviral RNA polymerases. , 2009, Biochimica et biophysica acta.

[57]  M. Cummings,et al.  1,5-Benzodiazepines, a Novel Class of Hepatitis C Virus Polymerase Nonnucleoside Inhibitors , 2008, Antimicrobial Agents and Chemotherapy.

[58]  Dusanka Janezic,et al.  Harmonic analysis of large systems. I. Methodology , 1995, J. Comput. Chem..

[59]  Jeffrey A Pfefferkorn,et al.  Inhibitors of HCV NS5B polymerase. Part 1: Evaluation of the southern region of (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid. , 2005, Bioorganic & medicinal chemistry letters.

[60]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[61]  Dashyant Dhanak,et al.  Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase. , 2009, Bioorganic & medicinal chemistry letters.

[62]  Haralambos Sarimveis,et al.  Identification of a series of novel derivatives as potent HCV inhibitors by a ligand-based virtual screening optimized procedure. , 2007, Bioorganic & medicinal chemistry.

[63]  A S Perelson,et al.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.

[64]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[65]  R. Nussinov,et al.  Allostery and population shift in drug discovery. , 2010, Current opinion in pharmacology.

[66]  C. Kao,et al.  Conformations of the monomeric hepatitis C virus RNA-dependent RNA polymerase , 2010 .